Mystery Cake Ruins Party For EpiPen TV Ad
This article was originally published in The Pink Sheet Daily
Executive Summary
Mylan direct-to-consumer ad misleadingly suggested that as long as allergy sufferers have the product with them, they don’t need to do anything else to avoid anaphylactic shock, FDA says.
You may also be interested in...
Patient-reported Outcome Claims On Kepivance Site Gets Full Throated FDA Response
SOBi’s oral mucositis treatment was studied in controlled trials that used patient-reported outcome measures, but their content validity has not been established, FDA’s Office of Prescription Drug Promotion says.
Mylan Breathes Life Into Its Specialty Pharma Unit
In its first investor meeting in four years, Mylan lays out plans to barge over the generics industry’s post-2013 so-called ‘reverse patent cliff’ by focusing on high-barrier-to-entry products – including generic Advair – and portfolio and geographic diversification.
FDA Deputizes Doctors In Hunt For "Bad Ads"
Outreach program, which asks for tips on worrisome promotional behavior, might be an effective deterrent even without finding many violations.